Connect with us

Business

Morgan Stanley Lowers Dynatrace Price Target to $43 Amid Analyst Activity

editorial

Published

on

Dynatrace (NYSE: DT) has seen its price target reduced by Morgan Stanley from $57.00 to $43.00, as reported in a note released on Tuesday. The firm maintains an equal weight rating on the stock, reflecting a cautious outlook amid varying assessments from other financial institutions.

Analysts continue to express differing views on Dynatrace’s future. Keefe, Bruyette & Woods upgraded the company’s rating to “buy” earlier this week. Conversely, Wells Fargo & Company lowered their target price from $65.00 to $50.00 while issuing an “overweight” rating. Raymond James Financial reaffirmed a “market perform” rating, whereas Jefferies Financial Group adjusted its price objective from $65.00 to $55.00, also maintaining a “buy” rating. Additionally, Stifel Nicolaus set a price target of $51.00.

Currently, twenty investment analysts rate Dynatrace with a “buy” designation, while seven have assigned it a “hold” rating. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $52.52.

Dynatrace Financial Performance and Future Guidance

Dynatrace announced its latest earnings results on February 9, 2026, reporting earnings per share (EPS) of $0.44, surpassing analysts’ expectations of $0.41 by $0.03. The company achieved revenue of $515.47 million for the quarter, exceeding the forecast of $506.31 million. The firm posted a net margin of 9.55% and a return on equity of 9.75%, with revenue growth of 18.2% year-over-year.

Dynatrace has set guidance for fiscal year 2026, projecting an EPS of between $1.670 and $1.690, with a fourth-quarter guidance of $0.380 to $0.390. Analysts anticipate an EPS of $0.68 for the current fiscal year.

In a notable move, Dynatrace’s board approved a stock repurchase program on February 9, 2026, allowing the company to buy back up to $1.00 billion in shares. This authorization permits the repurchase of approximately 9.8% of its stock, a strategy indicating the board’s belief that the shares are undervalued.

Insider Trading and Institutional Investments

Recent transactions involving company insiders have raised eyebrows. On December 10, 2025, Dan Zugelder, Executive Vice President, sold 7,505 shares at an average price of $45.27, totaling $339,751.35. Following this sale, Zugelder holds 8,925 shares, valued at approximately $404,034.75. This trade represented a 45.68% reduction in his holdings.

Additionally, Daniel S. Yates, Chief Accounting Officer, sold 2,000 shares on November 17, 2025, at an average price of $46.69, amounting to $93,380.00. After this transaction, Yates retained 23,380 shares, valued at around $1,091,612.20. Over the last quarter, insiders offloaded a total of 9,843 shares worth $448,124, with insiders currently owning 0.57% of the stock.

Institutional investors have also been active with Dynatrace shares. Vanguard Group Inc. increased its stake by 2.4% in the third quarter, now holding 32,142,909 shares valued at approximately $1.56 billion. Pictet Asset Management Holding SA raised its position by 16.5% in the fourth quarter, acquiring an additional 2,076,990 shares for a total of 14,648,533 shares valued at around $634.99 million.

Other notable institutional investors include State Street Corp., which boosted its stake by 2.8%, and American Century Companies Inc., which increased its position by 0.9%. Collectively, institutional investors and hedge funds now own 94.28% of Dynatrace’s stock.

As Dynatrace navigates a changing market landscape, the adjustments made by analysts, alongside the company’s recent financial performance and insider activities, will likely play a crucial role in shaping investor sentiment in the coming months.

Continue Reading

Trending

Copyright © All rights reserved. This website offers general news and educational content for informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the information provided. The content should not be considered professional advice of any kind. Readers are encouraged to verify facts and consult relevant experts when necessary. We are not responsible for any loss or inconvenience resulting from the use of the information on this site.